Thermo Fisher Scientific Inc. $TMO is Cryder Capital Partners LLP’s 7th Largest Position

Cryder Capital Partners LLP boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 344,676 shares of the medical research company’s stock after buying an additional 19,875 shares during the quarter. Thermo Fisher Scientific makes up approximately 7.9% of Cryder Capital Partners LLP’s portfolio, making the stock its 7th largest holding. Cryder Capital Partners LLP owned approximately 0.09% of Thermo Fisher Scientific worth $139,752,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Banco Santander S.A. grew its holdings in shares of Thermo Fisher Scientific by 7.5% during the second quarter. Banco Santander S.A. now owns 93,852 shares of the medical research company’s stock worth $38,053,000 after buying an additional 6,566 shares in the last quarter. Ashton Thomas Private Wealth LLC boosted its position in Thermo Fisher Scientific by 4.8% during the second quarter. Ashton Thomas Private Wealth LLC now owns 10,958 shares of the medical research company’s stock worth $4,448,000 after acquiring an additional 500 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its stake in Thermo Fisher Scientific by 172.5% during the 2nd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 19,073 shares of the medical research company’s stock valued at $7,765,000 after acquiring an additional 12,073 shares in the last quarter. Riverwater Partners LLC lifted its stake in Thermo Fisher Scientific by 16.1% in the 2nd quarter. Riverwater Partners LLC now owns 1,927 shares of the medical research company’s stock worth $781,000 after purchasing an additional 267 shares in the last quarter. Finally, Chilton Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 68.0% during the 2nd quarter. Chilton Capital Management LLC now owns 107,024 shares of the medical research company’s stock worth $43,394,000 after purchasing an additional 43,319 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $573.07 on Monday. The firm has a 50-day simple moving average of $504.04 and a two-hundred day simple moving average of $453.56. The stock has a market cap of $216.40 billion, a PE ratio of 33.11, a P/E/G ratio of 3.35 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock valued at $13,990,971 over the last ninety days. Insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday. Robert W. Baird lifted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating for the company. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, HSBC restated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Nineteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $595.75.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.